Process Chemistry Approach to the Total Synthesis of BMS-813160

BMS-813160 is being investigated by Bristol-Myers Squibb as a combination therapy for colorectal and pancreatic cancer. In order to evaluate the clinical efficacy, a safe, robust, scalable, and cost-effective total synthesis was needed. The talk will focus on how process chemists enabled the production of multi-kg of BMS-813160 by route invention, process invention, and process characterization. This case study will describe the synthetic challenges and highlight the pertinent difficulties to executing reactions on scale.

Speaker: Dr. Michael Fenster, Bristol-Myers Squibb